Skip to main content
Clinical Trials/DRKS00023806
DRKS00023806
Completed
Not Applicable

ong-term consequences of COVID-19 for pulmonary and neurocognitive disorders - COVIMMUNE-Clin

Klinik für Neurodegenerative Erkrankungen und GerontopsychiatrieUniversitätsklinikum Bonn0 sites162 target enrollmentMarch 16, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Klinik für Neurodegenerative Erkrankungen und GerontopsychiatrieUniversitätsklinikum Bonn
Enrollment
162
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 16, 2021
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Klinik für Neurodegenerative Erkrankungen und GerontopsychiatrieUniversitätsklinikum Bonn

Eligibility Criteria

Inclusion Criteria

  • Patient subjects must belong to one of the following: Asymptomatic or severly affected course of COVID\-19 (SARS\-CoV\-2 positive) infection. Both groups must meet the following criteria:
  • \- written informed consent of the subject
  • \- aged 25 to 75 years
  • \- fulfill the criteria for the respective groups of interest; either to the group of remitted COVID\-19 infection cases with an asymptomatic couse (i.e., no symptoms other than anosmia and/or ageusia) or to the group of remitted COVID\-19 infection cases with a severe course (i.e., requiring hospital stay)
  • \- able and willing to participate throughout the study
  • \- fluent German language abilities
  • Healthy controls will only be included if they meet all of the following criteria
  • \- written informed consent
  • aged 25 to 75 years
  • fluent German language abilities

Exclusion Criteria

  • \- inability to give informed consent
  • \- any condition that clearly interferes with participation in the study
  • \- any condition that interferes with the clinical or neuropsychological study procedures
  • \- sensory impairment that prevents or significantly interferes with neuropsychological testing
  • \- contraindication for MRI
  • \- severe or unstable medical condition
  • \- current major depressive episode
  • \- psychotic disorder, bipolar disorder, substance abuse at present or in the past
  • \- known neurodegenerative disorder (Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Huntington's disease, Amyotrophic Lateral Sclerosis)
  • \- vascular dementia, history of stroke, or history of malignant disease

Outcomes

Primary Outcomes

Not specified

Similar Trials